Yasmina Noubia Abdiche

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. doi Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet
    Yasmina Abdiche
    Rinat Laboratories, Pfizer Inc, South San Francisco, CA 94080, USA
    Anal Biochem 377:209-17. 2008
  2. pmc Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors
    Yasmina Noubia Abdiche
    Rinat Laboratories, Pfizer Inc, South San Francisco, California 94080, USA
    Protein Sci 17:1326-35. 2008
  3. ncbi Phosphoinositide-containing polymerized liposomes: stable membrane-mimetic vesicles for protein-lipid binding analysis
    Colin G Ferguson
    Echelon Biosciences Inc, 675 Arapeen Drive, Suite 302, Salt Lake City, Utah 84108, USA
    Bioconjug Chem 16:1475-83. 2005
  4. doi Exploring blocking assays using Octet, ProteOn, and Biacore biosensors
    Yasmina N Abdiche
    Rinat Laboratories, Biotherapeutics and Bioinnovation Center BBC, Pfizer Inc, South San Francisco, CA 94080, USA
    Anal Biochem 386:172-80. 2009
  5. pmc Determining the binding affinity of therapeutic monoclonal antibodies towards their native unpurified antigens in human serum
    Christine Bee
    Rinat, Pfizer Inc, South San Francisco, California, United States of America
    PLoS ONE 8:e80501. 2013
  6. pmc Exploring the dynamic range of the kinetic exclusion assay in characterizing antigen-antibody interactions
    Christine Bee
    Rinat, Pfizer Inc, South San Francisco, California, USA
    PLoS ONE 7:e36261. 2012
  7. doi Label-free epitope binning assays of monoclonal antibodies enable the identification of antigen heterogeneity
    Yasmina N Abdiche
    Rinat Pfizer Inc, South San Francisco, CA 94080, USA
    J Immunol Methods 382:101-16. 2012
  8. doi Expanding the ProteOn XPR36 biosensor into a 36-ligand array expedites protein interaction analysis
    Yasmina N Abdiche
    Rinat Pfizer Inc, South San Francisco, CA 94080, USA
    Anal Biochem 411:139-51. 2011
  9. doi The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis
    Alison M Betts
    Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc, Eastern Point Road, Groton, CT 06340, USA
    J Pharmacol Exp Ther 333:2-13. 2010
  10. pmc Appetite enhancement and weight gain by peripheral administration of TrkB agonists in non-human primates
    John C Lin
    Rinat, Pfizer Inc, South San Francisco, California, United States of America
    PLoS ONE 3:e1900. 2008

Collaborators

Detail Information

Publications11

  1. doi Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet
    Yasmina Abdiche
    Rinat Laboratories, Pfizer Inc, South San Francisco, CA 94080, USA
    Anal Biochem 377:209-17. 2008
    ..Our results provide a benchmark for assessing the performance of the above-mentioned sensors...
  2. pmc Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors
    Yasmina Noubia Abdiche
    Rinat Laboratories, Pfizer Inc, South San Francisco, California 94080, USA
    Protein Sci 17:1326-35. 2008
    ..The Biacore blocking assay that we designed was used to quantify the potency of tanezumab and is more precise and reproducible than the currently available cell-based functional assays...
  3. ncbi Phosphoinositide-containing polymerized liposomes: stable membrane-mimetic vesicles for protein-lipid binding analysis
    Colin G Ferguson
    Echelon Biosciences Inc, 675 Arapeen Drive, Suite 302, Salt Lake City, Utah 84108, USA
    Bioconjug Chem 16:1475-83. 2005
    ..The PIP(n) headgroups displayed on SPR sensors showed higher affinities for PH domains and PIP(n) monoclonal antibodies than did monomeric PIP(n)-analogues with biotinylated acyl chains...
  4. doi Exploring blocking assays using Octet, ProteOn, and Biacore biosensors
    Yasmina N Abdiche
    Rinat Laboratories, Biotherapeutics and Bioinnovation Center BBC, Pfizer Inc, South San Francisco, CA 94080, USA
    Anal Biochem 386:172-80. 2009
    ..The data from our different assay orientations and biosensors agree very well, establishing these machines as valuable tools for characterizing antibody epitopes and multiprotein complexes of biological significance...
  5. pmc Determining the binding affinity of therapeutic monoclonal antibodies towards their native unpurified antigens in human serum
    Christine Bee
    Rinat, Pfizer Inc, South San Francisco, California, United States of America
    PLoS ONE 8:e80501. 2013
    ..Our results highlight the importance of taking pH into account when measuring the affinities of mAbs towards their serum antigens, since the pH of serum samples becomes increasingly alkaline upon aerobic handling. ..
  6. pmc Exploring the dynamic range of the kinetic exclusion assay in characterizing antigen-antibody interactions
    Christine Bee
    Rinat, Pfizer Inc, South San Francisco, California, USA
    PLoS ONE 7:e36261. 2012
    ..We obtained excellent agreement in the apparent affinities obtained across platforms and within the KinExA method irrespective of the assay orientation employed or the purity of the recombinant or native antigens...
  7. doi Label-free epitope binning assays of monoclonal antibodies enable the identification of antigen heterogeneity
    Yasmina N Abdiche
    Rinat Pfizer Inc, South San Francisco, CA 94080, USA
    J Immunol Methods 382:101-16. 2012
    ..Furthermore, we provide recommendations for performing definitive binning assays and a diagnostic assay procedure that can be followed when antigen heterogeneity is suspected...
  8. doi Expanding the ProteOn XPR36 biosensor into a 36-ligand array expedites protein interaction analysis
    Yasmina N Abdiche
    Rinat Pfizer Inc, South San Francisco, CA 94080, USA
    Anal Biochem 411:139-51. 2011
    ..We apply alternative formats of the ProteOn array that enable a significantly higher number of assays to be conducted simultaneously than previously anticipated on this platform...
  9. doi The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis
    Alison M Betts
    Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc, Eastern Point Road, Groton, CT 06340, USA
    J Pharmacol Exp Ther 333:2-13. 2010
    ..It was concluded that the calculation of MABEL according to the TMDD model was the most appropriate means for ensuring safety and efficacy in clinical studies...
  10. pmc Appetite enhancement and weight gain by peripheral administration of TrkB agonists in non-human primates
    John C Lin
    Rinat, Pfizer Inc, South San Francisco, California, United States of America
    PLoS ONE 3:e1900. 2008
    ..Our findings revealed that TrkB signaling exerts dual control on energy homeostasis in the primates that could be targeted for the treatment of either wasting disorders or obesity...
  11. pmc High-throughput epitope binning assays on label-free array-based biosensors can yield exquisite epitope discrimination that facilitates the selection of monoclonal antibodies with functional activity
    Yasmina Noubia Abdiche
    Rinat Pfizer Inc, South San Francisco, California, United States of America
    PLoS ONE 9:e92451. 2014
    ..Thus, the complementary use of these two platforms can expedite applications that are relevant to the discovery of therapeutic mAbs, depending upon the sample availability, and the number and diversity of the interactions being studied. ..